Negoro S, Fukuoka M, Takada M, Tamai S, Sakai N, Matsui K
Gan To Kagaku Ryoho. 1982 Mar;9(3):522-8.
Eighteen previously untreated patients with squamous cell carcinoma of the lung were treated with a combination of a new bleomycin derivative, peplomycin and esquinon (PQ). One patient achieved a complete response (5.5%) and 5 patients a partial response (27.8%). Overall response rate was 33.3%. Median survival time of 6 patients with complete and partial response was 54 weeks and that of 12 patients with no change and progressive disease was 15 weeks. Toxicities included nausea and/or vomiting in 89%, fever in 61%, interstitial pneumonitis in 28% and leukopenia in 17%. PQ regimen appears to be effective in the treatment of squamous cell carcinoma of the lung.
18例既往未接受过治疗的肺鳞状细胞癌患者接受了一种新的博来霉素衍生物培普利欧霉素和艾斯喹农（PQ）联合治疗。1例患者达到完全缓解（5.5%），5例患者部分缓解（27.8%）。总缓解率为33.3%。6例完全缓解和部分缓解患者的中位生存时间为54周，12例病情无变化和疾病进展患者的中位生存时间为15周。毒性反应包括89%的患者出现恶心和/或呕吐，61%的患者发热，28%的患者出现间质性肺炎，17%的患者出现白细胞减少。PQ方案似乎对肺鳞状细胞癌的治疗有效。
